A Phase 3 interventional study of Terbinafine and Terbinafine Placebo in Tinea Pedis, sponsored by Novartis. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will compare the efficacy and safety of a single dose of terbinafine film forming solution 1% with a single dose of placebo film forming solution in the treatment of tinea pedis.
73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.
This study's enrollment of 290 is above the median of 128 across 66 interventional studies indexed under Tinea Pedis.
Browse Tinea Pedis studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug
Drug: Terbinafine
Drug
Drug: Terbinafine Placebo
1% single application
single application
Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)
Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptoms score the rating for all symptoms are added up. Possible range 0 to 18
Time frame: week 6
Total Clinical Signs and Symptoms (S/S) Scores
Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptom score, the scores for each individual symptom are added up. Possible range : 0 to 18
Time frame: week 6
Number of Subjects With Adverse Event
Number of Subjects with adverse event
Time frame: 6 weeks
Study start 27 Aug 2011 end 14 Feb 2012
| Milestone | Terbinafine | Placebo |
|---|---|---|
| Started | 145 | 145 |
| Completed | 118 | 128 |
| Not completed | 27 | 17 |
Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptoms score the rating for all symptoms are added up. Possible range 0 to 18
| participants | Terbinafine | Placebo |
|---|---|---|
| Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) | 73 | 10 |
Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale: 0 = absent 1. = mild 2. = moderate 3. = severe In order to calculate the total symptom score, the scores for each individual symptom are added up. Possible range : 0 to 18
| units on a scale | Terbinafine | Placebo |
|---|---|---|
| Total Clinical Signs and Symptoms (S/S) Scores | 1.6 (1.3 to 2.0) | 4.7 (4.1 to 5.2) |
Number of Subjects with adverse event
| participants | Terbinafine | Placebo |
|---|---|---|
| Number of Subjects With Adverse Event | 9 | 11 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Terbinafine | — | 0/146 (0%) | 0/146 (0%) |
| Placebo | — | 0/144 (0%) | 7/144 (4.9%) |
| Event | Terbinafine | Placebo |
|---|---|---|
| General DisordersGeneral disorders | 0/146 | 7/144 |
| Age, Continuous(years) | Terbinafine | Placebo | Total |
|---|---|---|---|
| Mean | 35.27 ± 12.805 | 34.05 ± 11.936 | 34.66 ± 12.372 |
| Sex: Female, Male(Participants) | Terbinafine | Placebo | Total |
|---|---|---|---|
| Female | 50 | 46 | 96 |
| Male | 95 | 99 | 194 |
The record gives a start of Aug 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terbinafine